Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 4 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 37.5%Moderate 1 · 12.5%High 0 · 0%

All‐cause mortality · patients with cancer with venous thromboembolism

Fondaparinux showed no clear difference in mortality compared with heparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 1.25 [0.86, 1.81]
1 study · 477 participants
Low

Recurrent VTE · patients with cancer with venous thromboembolism

Fondaparinux showed no clear difference in recurrent VTE compared with heparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.93 [0.56, 1.54]
1 study · 477 participants
Low

Major bleeding · patients with cancer with venous thromboembolism

Fondaparinux showed no clear difference in major bleeding compared with heparin (low certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 0.82 [0.4, 1.66]
1 study · 477 participants
Low

Minor bleeding · patients with cancer with venous thromboembolism

Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
RR 1.53 [0.88, 2.66]
1 study · 477 participants
Moderate

Quality of life ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombocytopenia · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Outcomes · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found